Avalo Therapeutics Inc expected to post a loss of 58 cents a share - Earnings Preview
Avalo Therapeutics Inc <AVTX.OQ> expected to post a loss of 58 cents a share - Earnings Preview
Avalo Therapeutics Inc AVTX.OQ AVTX.O is expected to show no change in quarterly revenue when it reports results on August 5 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Avalo Therapeutics Inc is for a loss of 58 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 15 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Avalo Therapeutics Inc is $43.50, about 138.4% above its last closing price of $18.25
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.98 | -1.03 | -0.98 | Beat | 4.4 |
Dec. 31 2026 | -1.39 | -1.46 | -1.13 | Beat | 22.8 |
Sep. 30 2025 | -1.67 | -1.66 | -2.19 | Missed | -32 |
Jun. 30 2025 | -1.40 | -1.40 | -1.92 | Missed | -36.7 |
Mar. 31 2025 | -1.40 | -1.39 | -1.25 | Beat | 9.9 |
Dec. 31 2024 | 0.25 | -0.39 | -7.95 | Missed | -1,929.8 |
Sep. 30 2024 | -1.10 | -1.19 | -1.25 | Missed | -5 |
Jun. 30 2024 | -6.70 | -6.70 | -14.07 | Missed | -110 |
This summary was machine generated August 3 at 13:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)